Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: GlobeNewswire
RANCHO CUCAMONGA, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has granted approval of its Abbreviated New Drug Application (“ANDA”) for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial. Amphastar’s newly approved drug product was determined by the FDA to be therapeutically equivalent to Adrenalin® (Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial) distributed in the United States by Par Pharmaceutical, Inc. Epinephrine Injection Multiple Dose Vial is for intramuscular, subcutaneous, and intravenous use, and is indicated for emergency treatment of allergic reactions (Type 1), including anaphylaxis, and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. Additionally, the FDA granted 180 day exclusivity to Amphastar as the first generic filer. Amphastar’s CEO and Preside
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $71.00 price target on the stock.MarketBeat
- BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLCPR Newswire
- With EPS Growth And More, Amphastar Pharmaceuticals (NASDAQ:AMPH) Makes An Interesting Case [Yahoo! Finance]Yahoo! Finance
- Hyaluronidase Market is Set to Grow at Staggering CAGR of 9.3% to Reach US$ 1,896.8 Million By 2032 | Astute Analytica [Yahoo! Finance]Yahoo! Finance
AMPH
Earnings
- 5/8/24 - Beat
AMPH
Sec Filings
- 6/28/24 - Form 4
- 6/27/24 - Form 144
- 6/11/24 - Form 4
- AMPH's page on the SEC website